Williams Jones Wealth Management LLC. Grows Stake in Quanterix Co. (NASDAQ:QTRX)

Williams Jones Wealth Management LLC. lifted its holdings in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 39.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 471,514 shares of the company's stock after acquiring an additional 134,470 shares during the period. Williams Jones Wealth Management LLC. owned 1.22% of Quanterix worth $5,012,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Quanterix by 1.8% during the fourth quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after purchasing an additional 1,963 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after buying an additional 3,915 shares during the period. Hsbc Holdings PLC lifted its stake in Quanterix by 25.8% in the fourth quarter. Hsbc Holdings PLC now owns 19,371 shares of the company's stock valued at $205,000 after buying an additional 3,974 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after buying an additional 4,000 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Quanterix by 21.9% in the fourth quarter. MetLife Investment Management LLC now owns 23,983 shares of the company's stock valued at $255,000 after acquiring an additional 4,303 shares during the period. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Price Performance

NASDAQ:QTRX opened at $4.99 on Wednesday. The firm has a market cap of $193.76 million, a price-to-earnings ratio of -4.71 and a beta of 1.12. The firm's fifty day moving average price is $5.78 and its 200 day moving average price is $8.69. Quanterix Co. has a 1-year low of $4.05 and a 1-year high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $30.33 million during the quarter, compared to analysts' expectations of $28.27 million. As a group, analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on QTRX. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Leerink Partners restated a "market perform" rating and issued a $8.00 price objective (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Canaccord Genuity Group decreased their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $15.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.